Legacy Capital Wealth Partners’s GSK GSK Stock Holding History

Legacy Capital Wealth Partners’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$779K	Sell	14,870 -44	-0.3%	-$2.33K	0.15%	137
2026 Q1	$823K	Sell	14,914 -4,872	-25%	-$264K	0.17%	125
2025 Q4	$970K	Sell	19,786 -1,888	-9%	-$88.1K	0.21%	96
2025 Q3	$935K	Buy	21,674 +60	+0.3%	+$2.34K	0.2%	102
2025 Q2	$830K	Sell	21,614 -252	-1%	-$9.63K	0.19%	109
2025 Q1	$847K	Buy	21,866 +5,778	+36%	+$212K	0.21%	101
2024 Q4	$544K	Sell	16,088 -23,681	-60%	-$852K	0.13%	156
2024 Q3	$1.63M	Buy	39,769 +20,211	+103%	+$827K	0.33%	61
2024 Q2	$753K	Buy	+19,558	New	+$823K	0.19%	99
2024 Q1	–	Sell	-18,285	Closed	-$678K	–	206
2023 Q4	$678K	Sell	18,285 -664	-4%	-$23.8K	0.19%	111
2023 Q3	$687K	Buy	+18,949	New	+$673K	0.19%	113
2023 Q2	–	Sell	-13,743	Closed	-$489K	–	121
2023 Q1	$489K	Buy	+13,743	New	+$481K	0.13%	138

Other funds holding GSK

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.25B AUM 41.83% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Legacy Capital Wealth Partners's GSK Position: Q2 2026 in Review

Legacy Capital Wealth Partners reduced its GSK (GSK) stake by 0.3% in Q2 2026, selling an estimated $2.33K and leaving 14,870 shares worth $779K. The position accounts for 0.15% of the portfolio, ranked #137.

Legacy Capital Wealth Partners first reported a position in GSK in Q1 2023 and has held it in 12 quarters since. The position peaked at $1.63M in Q3 2024. 1,038 funds tracked by Wall St. Rank hold GSK as of Q2 2026.

Legacy Capital Wealth Partners held 14,870 shares of GSK worth $779K as of Q2 2026.
Legacy Capital Wealth Partners sold 44 GSK shares in Q2 2026, an estimated $2.33K.
GSK made up 0.15% of Legacy Capital Wealth Partners's portfolio in Q2 2026, its #137 holding.
Legacy Capital Wealth Partners first reported a position in GSK in Q1 2023 and has held it in 12 quarters since.
Legacy Capital Wealth Partners's GSK position peaked at $1.63M in Q3 2024.
1,038 funds tracked by Wall St. Rank held GSK as of Q2 2026.

Based on Legacy Capital Wealth Partners's 13F filing for Q2 2026, filed 12 Aug 2026.